Core E Animal Infection Models

Core E 动物感染模型

• 批准号: 10613892
• 负责人: David S Perlin
• 金额: $ 144.96万
• 依托单位: HACKENSACK UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10613892
• 关键词: Acceleration; Acute; Aerosols; Animal Model; Animals; Bacteremia; Bacteria; Biological Assay; Biological Markers; Biotechnology; Chronic; Clinical; Communication; Cutaneous; Data; Dedications; Development; Disease; Disease Marker; Disease model; ESKAPE pathogens; Histopathology; Human Resources; Immune response; Infection; Inflammation; Institution; Lead; Lung; Lung infections; Mass Spectrum Analysis; Measurement; Methods; Modeling; Molecular; Morbidity - disease rate; Mucous Membrane; Multi-Drug Resistance; Multidrug-Resistant Tuberculosis; Multiple Bacterial Drug Resistance; Mus; Mycobacterium tuberculosis; Oral; Penetration; Pharmaceutical Preparations; Pneumonia; Reproducibility; Rodent; Route; Sepsis; Services; Site; Skin Tissue; Soft Tissue Infections; Spatial Distribution; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Systemic infection; Therapeutic; Thigh structure; Tissues; Treatment Efficacy; Tuberculosis; Work; acute infection; analytical method; biodefense; chronic infection; design; drug development; drug resistant bacteria; drug resistant pathogen; experience; fluorescence imaging; in vivo; in vivo imaging; innovation; instrumentation; laser capture microdissection; liquid chromatography mass spectrometry; lung lesion; microbial; mortality; multi-drug resistant pathogen; new technology; next generation; non-tuberculous mycobacterial infection; novel; pathogen; pathogenic bacteria; pre-clinical; preclinical development; soft tissue; specific biomarkers; spectroscopic imaging; subcutaneous; treatment response; wound

Abstract Assessing the treatment efficacy of novel leads against drug resistant bacteria in animal models is crucial for advancing compounds to the preclinical stage of development. Currently, there is a paucity of reproducible disease models with reliable metrics to assess lead compounds and even less facilities and personnel with the expertise to perform such important studies. To meet this important challenge, the Animal Model Core for this proposed CETR has developed reproducible systemic, pulmonary, soft tissue, wound, infection models in rodents for clinically important multidrug resistant bacteria. The Aims of the core are to: 1) provide small animal infection models for ESKAPE, TB and NTM pathogens to evaluate lead compounds, and 2) provide state of the art analytical services on host response and bacterial bio-burden distribution to assess and quantify lead compound treatment efficacy. The Animal core has functioned in this capacity for more than 15 years with experience supporting drug development for the academic, pharma and biotech sectors. Under the direction of Dr. David Perlin, it served as a multi-institutional regional animal core for the Region II RCE (Northeast Biodefense Center) for 11 years (2003-2013) and has supported the current CETR for the past 4+ years (2013 to present). The Animal Core operates at a very high capacity, having logged more than 1.8 million animal days of high threat bacterial agents since 2003. An experienced and dedicated animal model team performs a wide range of infection models with multiple routes of infections (iv, oral, aerosol, subcutaneous, mucosal) and markers for disease (morbidity/mortality, microbial burden, histopathology, etc.). The management staff of the Animal core works closely with both Project Leaders and other Core Directors to ensure that all novel leads are rapidly advanced through the development pipeline. This close and constant line of communication permits the necessary adjustments in design and execution of studies, and has resulted in the advancement of 7 promising leads in the Rutgers CETR projects from 2014 to 2018. the Animal core possesses cutting edge instrumentation for analysis of infections and therapeutic responses. The incorporation of reproducible animal models operated by highly experienced staff and utilizing novel technologies will advance and accelerate the development of promising Lead compounds against multidrug resistant bacteria. All services can be performed under high-level biocontainment with regulatory approval. !

抽象的 评估动物模型中新型铅针对耐药细菌的治疗功效 对于将化合物推向发展的临床前阶段至关重要。目前，有一个 缺乏可再现疾病模型具有可靠指标以评估铅化合物甚至 具有专业知识的设施和人员来进行此类重要研究。满足这个 重要的挑战，该提出的CERT的动物模型核心已发展为可重复的 全身性，肺部，软组织，伤口，感染模型，用于临床重要的 多药耐药细菌。核心的目的是：1）提供小动物感染模型 对于Eskape，TB和NTM病原体评估铅化合物，2）提供最新的状态 宿主响应和细菌生物责任分布的分析服务，以评估和量化 铅复合治疗功效。动物核心的功能超过了 15年具有支持学术，制药和生物技术药物开发的经验 部门。在戴维·珀林（David Perlin）博士的指导下，它是一种多机构的区域动物 该地区II RCE（东北生物浮雕中心）的核心已有11年（2003- 2013年），并具有 在过去的4年以上（2013年）支持当前的CERTER。动物核心运作 以非常高的能力记录了超过180万个高威胁细菌的动物日 自2003年以来的代理商。一个经验丰富且敬业的动物模型团队执行了广泛的范围 感染模型具有多种感染途径（IV，口服，气溶胶，皮下，粘膜）和 疾病标记（发病/死亡率，微生物负担，组织病理学等）。这 动物核心的管理人员与项目领导者和其他核心密切合作 董事确保所有新型潜在客户都可以通过开发管道迅速发展。 这种紧密而恒定的沟通线可以在设计中进行必要的调整和 执行研究，并导致了罗格人的7个有希望的潜在客户 Cetr项目从2014年到2018年。动物核心具有尖端仪器 分析感染和治疗反应。可再生动物模型的结合 由经验丰富的员工运营并利用新技术将进步和加速 针对多药抗性细菌的有希望的铅化合物的发展。所有服务 可以在高级生物内在的情况下进行监管批准。 呢